- ICH GCP
- Registro de ensaios clínicos dos EUA
- Ensaio Clínico NCT06850038
Um estudo observando a eficácia e a segurança de longo prazo do ODEVIXIBAT (BYLVAY) em pacientes com síndrome de Alagille (ALGs) que estão recebendo tratamento contínuo
Estudo prospectivo baseado em registro, avaliando a eficácia e a segurança do Odevixibat em participantes com a síndrome de Alagille (ALGs)
This study will collect information from patients with Alagille syndrome (ALGS) as they use odevixibat (Bylvay) in their daily lives.
Odevixibat is a medicine that helps patients with ALGS, a rare disease that harms their liver and causes itching.
The main aim of this study is to observe the long-term, everyday effectiveness and safety of the drug odevixibat in patients with ALGS who are receiving ongoing treatment.
Visão geral do estudo
Status
Condições
Tipo de estudo
Inscrição (Estimado)
Contactos e Locais
Contato de estudo
- Nome: Ipsen Recruitment Enquiries
- Número de telefone: See email
- E-mail: clinical.trials@ipsen.com
Locais de estudo
-
-
California
-
Los Angeles, California, Estados Unidos, 90027
- Recrutamento
- Children's Hospital Los Angeles
-
San Francisco, California, Estados Unidos, 94158
- Recrutamento
- UCSF Benioff Children's Hospital
-
-
Missouri
-
Kansas City, Missouri, Estados Unidos, 64108
- Recrutamento
- The Children's Mercy Hospital
-
St Louis, Missouri, Estados Unidos, 63104
- Recrutamento
- SSM Health Cardinal Glennon Children's Hospital
-
-
New York
-
New York, New York, Estados Unidos, 10016
- Recrutamento
- NYU Langone - NYU Grossman School of Medicine
-
New York, New York, Estados Unidos, 10032
- Recrutamento
- Columbia University Medical Center - Morgan Stanley Children's Hospital of NewYork - Presbyterian (MS-CHONY)
-
-
Tennessee
-
Memphis, Tennessee, Estados Unidos, 38105
- Recrutamento
- Le Bonheur Children's Hospital
-
-
Texas
-
Dallas, Texas, Estados Unidos, 75246
- Recrutamento
- Children's Medical Center Of Dallas
-
El Paso, Texas, Estados Unidos, 79902
- Recrutamento
- Proactive El Paso,LLC
-
-
Utah
-
Salt Lake City, Utah, Estados Unidos, 84113
- Ainda não está recrutando
- Primary Children's Hospital (PCH) - Intermountain Healthcare/University of Utah
-
-
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
- Filho
- Adulto
- Adulto mais velho
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Método de amostragem
População do estudo
Patients diagnosed with ALGS who start treatment with odevixibat (Bylvay) will be enrolled into the registry. Patients who started odevixibat treatment before the implementation of the registry study may also be enrolled.
Descrição
Inclusion Criteria:
- Diagnosed with ALGS.
- On (or starting) active odevixibat treatment.
- Signed informed consent and assent, as appropriate. Consent/assent from the participant or legal representative should be obtained, as appropriate, before any study data collection is conducted. Participants who turn 18 years of age (or legal age per country) while participating in the study will be required to provide consent for themselves.
Exclusion Criteria:
- Currently participating in a clinical trial with odevixibat.
- Currently participating in any interventional clinical trial for ALGS.
- Have any contraindication to odevixibat as per the locally approved label.
- Had liver transplant before enrolment
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Modelos de observação: OTHER
- Perspectivas de Tempo: PROSPECTIVE
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Porcentagem de participantes com síndrome de Alagille (ALGs) que são tratados com Odevixibat e passam por cirurgia de desvio biliar ou transplante de fígado.
Prazo: Da primeira dose ao final do estudo (aproximadamente 5 anos de coleta de dados)
|
Da primeira dose ao final do estudo (aproximadamente 5 anos de coleta de dados)
|
|
|
Surgical biliary diversion-free survival
Prazo: From first dose to end of study (approximately 5 years data collection)
|
Defined as time from the start of odevixibat treatment to the first occurrence of surgical biliary diversion or death. |
From first dose to end of study (approximately 5 years data collection)
|
|
Liver transplant-free survival
Prazo: From first dose to end of study (approximately 5 years data collection)
|
Defined as time from the start of odevixibat treatment to the first occurrence of liver transplant or death. |
From first dose to end of study (approximately 5 years data collection)
|
|
Overall survival
Prazo: From first dose to end of study (approximately 5 years data collection)
|
Defined as time from the start of odevixibat treatment to death. |
From first dose to end of study (approximately 5 years data collection)
|
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Change from Baseline in Weight
Prazo: From first dose to end of study (approximately 5 years data collection)
|
This endpoint will measure the change in participants' weight from baseline, reported as standard-deviation scores (z-scores) to account for age and sex-specific growth variations. |
From first dose to end of study (approximately 5 years data collection)
|
|
Change from Baseline in Height
Prazo: From first dose to end of study (approximately 5 years data collection)
|
This endpoint will measure the change in participants' height from baseline, reported as standard-deviation scores (z-scores) to account for age and sex-specific growth variations. |
From first dose to end of study (approximately 5 years data collection)
|
|
Percentage of participants with Adverse Events (AEs) associated with fat-soluble vitamin (FSV) deficiencies and their possible sequelae.
Prazo: From signing of the Informed Consent Form (ICF) to 180 days after the last dose intake of odevixibat
|
An Adverse event (AE) is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. |
From signing of the Informed Consent Form (ICF) to 180 days after the last dose intake of odevixibat
|
|
Percentage of participants with suspected hepatotoxic Adverse events (AEs) requiring interruption of odevixibat
Prazo: From signing of the ICF to 180 days after the last dose intake of odevixibat
|
An Adverse event (AE) is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. |
From signing of the ICF to 180 days after the last dose intake of odevixibat
|
|
Percentage of participants with bleeding AEs
Prazo: From signing of the ICF to 180 days after the last dose intake of odevixibat
|
An Adverse event (AE) is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. |
From signing of the ICF to 180 days after the last dose intake of odevixibat
|
|
Percentage of participants with AEs
Prazo: From signing of the ICF to 180 days after the last dose intake of odevixibat
|
An Adverse event (AE) is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. |
From signing of the ICF to 180 days after the last dose intake of odevixibat
|
Colaboradores e Investigadores
Patrocinador
Investigadores
- Diretor de estudo: Ipsen Medical, Director, Ipsen
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Real)
Conclusão Primária (Estimado)
Conclusão do estudo (Estimado)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Real)
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Termos MeSH relevantes adicionais
- Doenças cardiovasculares
- Doenças Genéticas, Congênitas
- Doenças do aparelho digestivo
- Doenças das vias biliares
- Doenças do Fígado
- Anomalias congénitas
- Anormalidades cardiovasculares
- Defeitos Cardíacos Congênitos
- Anormalidades, Múltiplas
- Doenças das vias biliares
- Colestase Intra-hepática
- Colestase
- Doenças e Anormalidades Congênitas, Hereditárias e Neonatais
- Síndrome de Alagille
Outros números de identificação do estudo
- CLIN-60240-033
Plano para dados de participantes individuais (IPD)
Planeja compartilhar dados de participantes individuais (IPD)?
Descrição do plano IPD
Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, annotated case report form, statistical analysis plan, and dataset specifications.
Patient level data will be anonymized and study documents will be redacted to protect the privacy of study participants.
Prazo de Compartilhamento de IPD
Where applicable, data from eligible studies are available 6 months after the studied medicine and indication have been approved in the US and/or EU.
Critérios de acesso de compartilhamento IPD
Further details on Ipsen's sharing criteria and process for sharing are available here (https://www.ipsen.com/science/clinical-trials/clinical-data-transparency/).
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
produto fabricado e exportado dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .